By Brazil Stock Guide – Oncoclínicas do Brasil Serviços Médicos SA (ONCO3) moved closer to a potential boardroom shakeup after authorizing the call of an extraordinary shareholders’ meeting requested by investors holding more than 14% of the company’s voting capital. The decision, recorded in board minutes made public on Thursday (Dec. 11), opens the door to the removal of the entire board of directors and the election of a new slate.
The authorization was approved unanimously at a board meeting held on Dec. 2, according to the minutes disclosed to the market. The request was filed by three investment funds managed by Latache Gestão de Recursos, which invoked Brazil’s corporate law provisions allowing minority shareholders above a minimum threshold to demand an extraordinary general meeting. The proposed agenda includes dismissing all current board members, resetting the board’s size, electing new directors, assessing their independence and appointing a new chair and vice-chair.
Formal Shareholder Pressure
The minutes state that the requesting shareholders collectively hold more than 14% of Oncoclínicas’ outstanding common shares, exceeding the legal threshold required to force the meeting. The board also approved management’s proposal to be submitted to shareholders and authorized executives to take all necessary steps to convene the extraordinary meeting, including regulatory filings and mandatory disclosures.
The company said it is in the final stage of gathering the information required to formally call the meeting and will keep investors informed as the process advances. Oncoclínicas did not disclose a date for the extraordinary meeting. Once the notice is published, statutory deadlines under Brazilian corporate law will apply.
What Is at Stake
The move highlights escalating tensions between investors and management as Oncoclínicas faces mounting scrutiny over its capital strategy. The company has been under pressure from shareholders after carrying out multiple capital injections in recent years, following an aggressive expansion of its business. Oncoclínicas also counted Banco Master as a shareholder and disclosed exposure to debt securities issued by the lender, which was later liquidated by regulators — a sequence of events that has intensified governance concerns among investors.
If approved, the shareholder proposal would trigger one of the most comprehensive board overhauls seen in Brazil’s listed healthcare sector in recent years. In the short term, the process is likely to add volatility to Oncoclínicas’ shares. Over the medium term, investors will assess whether a reset at the top can redefine strategy and restore market confidence in one of the country’s most visible cases of shareholder activism.
Leave a Reply